#	Pagina
attuale pagina	/open-h2020/projects/199999/index.html

Opendata, web and dolomites

IMPEDE

Immunomodulatory effects of sustained pantethine release in inflammatory diseases

Total Cost €

EC-Contrib. €

Partnership

Views

IMPEDE project word cloud

Explore the words cloud of the IMPEDE project. It provides you a very rough idea of what is the project "IMPEDE" about.

stand neurotrafficking trafficking natural ip models close provides data society enormous business rapid auto degradation effectiveness either protects antiinflammatory diseases formulation disulphide cure patent ms strategy worldwide rheumatoid brain devoid proprietary alone autoimmune perform burden found 648b subsequent patients stg globally grant multiple causes ra people filed modulates strategies huge hydrolysis effect coap immune 120m treatment inflammatory 45b disease limited precursor offers treatments molecule bonds market generate erc coenzyme socioeconomic therapeutic arthritis anti gut validate intact ad impede inflammation fast derivatives breakdown preliminary sclerosis regulatory prepare reducing combination mouse alzheimer leukocyte

Project "IMPEDE" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITA DEGLI STUDI DI VERONA Organization address address: VIA DELL ARTIGLIERE 8 city: VERONA postcode: 37129 website: www.univr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2015-PoC
Funding Scheme	ERC-POC
Starting year	2016
Duration (year-month-day)	from 2016-02-01 to 2017-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI VERONA UNIVERSITA DEGLI STUDI DI VERONA Organization address address: VIA DELL ARTIGLIERE 8 city: VERONA postcode: 37129 website: www.univr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (VERONA)	coordinator	150˙000.00

Map

Project objective

Auto-immune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA) and inflammation-associated brain diseases including Alzheimer's disease (AD) globally make up a €45B market and cost society close to €648B. The huge number of patients with these diseases causes an enormous socioeconomic burden. Currently, MS, AD and RA affect 120M people worldwide. There is no cure for AD and treatments for autoimmune diseases are not fully effective and reducing the inflammatory component in these diseases is a key strategy. As a result of our ERC StG NEUROTRAFFICKING we found that a natural molecule, which is Coenzyme A precursor (CoAP), modulates leukocyte trafficking and has anti-inflammatory properties that are, however, limited in effectiveness due to fast breakdown in the gut. Our preliminary data demonstrate that derivatives of CoAP hydrolysis are devoid of antiinflammatory effects and that intact CoAP is required for its therapeutic effect in mouse models of MS and AD. The goal of IMPEDE is to develop a proprietary formulation of CoAP that protects it from hydrolysis and its disulphide bonds from degradation. This provides a novel and highly promising therapeutic approach for the inflammatory diseases, either for combination or stand-alone treatment. A patent application for this novel CoAP formulation has been filed. Subsequent steps will be taken in IMPEDE to generate and validate a more effective product through improved formulation and to prepare further regulatory and IP strategies, design a business strategy and perform market research. Overall, IMPEDE offers a rapid valorisation of the ERC StG grant on one hand and of the novel CoAP formulation on the other hand. It will generate a novel CoAP formulation with high therapeutic potential in autoimmune diseases and other inflammatory diseases.

Publications

List of publications.
year	authors and title	journal	last update
2017	Elena Zenaro, Gennj Piacentino, Gabriela Constantin The blood-brain barrier in Alzheimer\'s disease published pages: 41-56, ISSN: 0969-9961, DOI: 10.1016/j.nbd.2016.07.007	Neurobiology of Disease 107	2019-07-22
2017	Enrica Caterina Pietronigro, Vittorina Della Bianca, Elena Zenaro, Gabriela Constantin NETosis in Alzheimerâ€™s Disease published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2017.00211	Frontiers in Immunology 8	2019-07-22
2016	Barbara Rossi, Gabriela Constantin Live Imaging of Immune Responses in Experimental Models of Multiple Sclerosis published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2016.00506	Frontiers in Immunology 7	2019-07-22
2016	Enrica Pietronigro, Elena Zenaro, Gabriela Constantin Imaging of Leukocyte Trafficking in Alzheimerâ€™s Disease published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2016.00033	Frontiers in Immunology 7	2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPEDE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPEDE" are provided by the European Opendata Portal: CORDIS opendata.